Table 2.
Prevalence of cytomegalovirus (CMV) in patients with inflammatory bowel disease and healthy controls
| |
IBD |
UC |
CD |
Healthy controls |
|---|---|---|---|---|
| (n = 226) | (n = 189) | (n = 37) | (n = 290) | |
| CMV detection |
n (%) |
n (%) |
n (%) |
n (%) |
| DNA DNA+ |
90 (84.07)a |
161 (85.19)d |
29 (78.38)g |
173 (59.66) |
| Serum CMV IgG+ |
172 (76.11)b |
139 (73.54)e |
33 (89.19)h |
147 (50.69) |
| Serum CMV IgM+ | 4 (1.77)c | 3 (1.59)f | 1 (2.70)i | 1 (0.34) |
a Compare with healthy controls, OR = 3.569, 95% CI: 2.330-5.468, P < 0.001;
b Compare with healthy controls, OR = 3.099, 95% CI: 2.113-4.543, P < 0.001;
c Compare with healthy controls, OR = 5.207, 95% CI: 0.578-46.914, P = 0.235;
d Compare with healthy controls, OR = 3.889, 95% CI:2.443-6.190, P < 0.001;
e Compare with healthy controls, OR = 2.704, 95% CI:1.819-4.022, P < 0.001;
f Compare with healthy controls, OR = 4.661, 95% CI:0.481-45.148, P = 0.344;
g Compare with healthy controls, OR = 2.452, 95% CI:1.083-5.550, P = 0.027;
h Compare with healthy controls, OR = 8.026, 95% CI:2.772-23.232, P < 0.001;
i Compare with healthy controls, OR = 8.028, 95% CI:0.491-131.142, P = 0.540.
IBD, inflammatory bowel disease; CMV, cytomegalovirus; UC, ulcerative colitis; CD, Crohn’s disease.